Moxifloxacin Solid Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name : Moxifloxacin Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company : MSD
Shotton Lane
NE23 3JU Cramlington NU - Great Britain
Telephone : 44 1 670 59 30 00
Telefax : 908-735-1496
E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)
Acute toxicity, Category 4 : H302: Harmful if swallowed.
Eye irritation, Category 2 : H319: Causes serious eye irritation.
Reproductive toxicity, Category 2 : H361d: Suspected of damaging the unborn child.
Specific target organ toxicity - repeated exposure, Category 2 : H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms : 
Signal word : Warning
Hazard statements : H302 Harmful if swallowed.
H319 Causes serious eye irritation.
H361d Suspected of damaging the unborn child.
H373 May cause damage to organs through prolonged or repeated exposure.
Precautionary statements:

**Prevention:**
P201 Obtain special instructions before use.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.

Hazardous components which must be listed on the label:
Moxifloxacin HCL

**2.3 Other hazards**
None known.

**SECTION 3: Composition/information on ingredients**

**3.2 Mixtures**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moxifloxacin HCL</td>
<td>186826-86-8</td>
<td>Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 2; H373</td>
<td>&gt;= 40 - &lt;= 70</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures**

**4.1 Description of first aid measures**

**General advice:** In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

**Protection of first-aiders:** First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**If inhaled:** If inhaled, remove to fresh air. Get medical attention.
In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed
Risks: Harmful if swallowed. Causes serious eye irritation. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

5.3 Advice for firefighters
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not swallow. Do not get in eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working area.
place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Occupational Exposure Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Components</td>
</tr>
<tr>
<td>Moxifloxacin HCL</td>
</tr>
<tr>
<td>Cellulose</td>
</tr>
<tr>
<td>Further information</td>
</tr>
</tbody>
</table>
8.2 Exposure controls

Engineering measures
Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye protection
: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection
Material : Chemical-resistant gloves

Skin and body protection
: Work uniform or laboratory coat.

Respiratory protection
: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : solid

Colour : pink

Odour : odourless

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : Not classified as a flammability hazard

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available
Moxifloxacin Solid Formulation

Vapour pressure : No data available
Relative vapour density : No data available
Relative density : No data available
Density : No data available
Solubility(ies)
   Water solubility : No data available
Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
   Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information
Flammability (liquids) : No data available
Molecular weight : Not applicable
Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : None known.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.
SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of exposure:
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Harmful if swallowed.

Product:
Acute oral toxicity:
Acute toxicity estimate: 1,886 mg/kg
Method: Calculation method

Components:
Moxifloxacin HCL:
Acute oral toxicity:
LD50 (Rat): 1,320 mg/kg
LD50 (Mouse): > 435 mg/kg
LD50 (Monkey): 1,500 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Moxifloxacin HCL:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:
Moxifloxacin HCL:
Species: Rabbit
Result: Moderate eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.
Moxifloxacin Solid Formulation

Components:
Moxifloxacin HCL:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: positive
- Test Type: Chromosome aberration test in vitro
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Result: negative
- Test Type: In vitro micronucleus test
  Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Application Route: Oral
  Result: negative

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Suspected of damaging the unborn child.

Components:
Moxifloxacin HCL:
Effects on fertility:
- Test Type: Fertility/early embryonic development
  Species: Rat
  Application Route: Oral
  Fertility: LOAEL: 500 mg/kg body weight
  Result: Effects on fertility

Effects on foetal development:
- Test Type: Embryo-foetal development
  Species: Monkey
  Application Route: Oral
  Developmental Toxicity: NOAEL: 10 mg/kg body weight
  Result: negative

  Test Type: Embryo-foetal development
  Species: Rabbit
  Application Route: Intravenous injection
  Developmental Toxicity: LOAEL: 20 mg/kg body weight
  Symptoms: Skeletal malformations

Reproductive toxicity - Assessment:
Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.
STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

Moxifloxacin HCL:
Target Organs: Liver
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Moxifloxacin HCL:
Species: Rat
LOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 4 Weeks

Species: Rat
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Liver
Symptoms: Liver disorders

Species: Rat
NOAEL: 20 mg/kg
Application Route: Oral
Exposure time: 6 Months
Target Organs: Liver
Symptoms: Liver disorders

Species: Monkey
NOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 4 Weeks
Symptoms: No adverse effects

Species: Monkey
NOAEL: 15 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Gastrointestinal tract
Symptoms: Vomiting

Species: Monkey
Application Route: Oral
Exposure time: 26 Weeks
Target Organs: Liver
Symptoms: Liver disorders
Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Moxifloxacin HCL:
Ingestion:
Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain

SECTION 12: Ecological information

12.1 Toxicity
No data available

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential
No data available

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product:
Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging:
Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Moxifloxacin Solid Formulation

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EC) No 850/2004 on persistent organic pollutants: Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable


Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version
Moxifloxacin Solid Formulation

Full text of H-Statements

H302 : Harmful if swallowed.
H319 : Causes serious eye irritation.
H361d : Suspected of damaging the unborn child.
H373 : May cause damage to organs through prolonged or repeated exposure.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Eye Irrit. : Eye irritation
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure
GB EH40 : UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA : Long-term exposure limit (8-hour TWA reference period)
GB EH40 / STEL : Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECS - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information
Moxifloxacin Solid Formulation

Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:

<table>
<thead>
<tr>
<th></th>
<th>Classification procedure:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Tox. 4</td>
<td>H302</td>
</tr>
<tr>
<td>Eye Irrit. 2</td>
<td>H319</td>
</tr>
<tr>
<td>Repr. 2</td>
<td>H361d</td>
</tr>
<tr>
<td>STOT RE 2</td>
<td>H373</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

GB / EN